7.4 Post-Cardiac Arrest Care, Targeted Temperature Management & Neuroprognostication

ABIM Critical Care Medicine Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Orientation: Format, Blueprint & Study Strategy

1.1 ABIM Critical Care Medicine Exam: Format, Blueprint & Study Strategy

2 Chapter 2: Acute Respiratory Failure & ARDS

2.1 ARDS Definition, Pathophysiology & Phenotypes 2.2 Lung-Protective Mechanical Ventilation 2.3 Refractory ARDS: Prone Positioning, Neuromuscular Blockade & VV-ECMO

3 Chapter 3: Obstructive Airways, Pulmonary Vascular & Pleural Emergencies

3.1 Severe Asthma & COPD Exacerbations in the ICU 3.2 Massive & Submassive Pulmonary Embolism 3.3 Pulmonary Hypertension & Right Ventricular Failure in the ICU 3.4 Massive Hemoptysis, Complex Pleural Effusions & Thoracic Drainage

4 Chapter 4: Airway, Parenchymal & Nonthrombotic Pulmonary Emergencies

4.1 Airway Management, Upper-Airway Obstruction & Artificial-Airway Complications 4.2 Diffuse Alveolar Hemorrhage, Interstitial Lung Disease, Pulmonary Vasculitis & Noncardiogenic Edema 4.3 Severe Community-Acquired & Viral Pneumonia 4.4 Nonthrombotic Embolism (Air, Fat, Amniotic Fluid, Tumor, Septic) & Acute Chest Syndrome

5 Chapter 5: Mechanical Ventilation Modes, Dyssynchrony & Liberation

5.1 Mechanical Ventilator Modes & Advanced Breath Delivery 5.2 Patient-Ventilator Dyssynchrony & Waveform Analysis 5.3 Ventilator Liberation, Spontaneous Breathing Trials & Post-Extubation Support

6 Chapter 6: Shock Syndromes & Hemodynamic Principles

6.1 Shock Classification, Cellular Pathophysiology & Biomarkers 6.2 Hemodynamic Monitoring: Arterial Lines, CVP & Pulmonary Artery Catheter 6.3 Dynamic Assessment of Fluid Responsiveness & Resuscitation Targets

7 Chapter 7: Vasoactive Therapies & Mechanical Circulatory Support

7.1 Vasopressors & Inotropes: Pharmacology & Clinical Titration 7.2 Temporary Mechanical Circulatory Support: IABP, Impella & TandemHeart 7.3 Venoarterial ECMO (VA-ECMO) & Differential Hypoxemia 7.4 Post-Cardiac Arrest Care, Targeted Temperature Management & Neuroprognostication

8 Chapter 8: Acute Kidney Injury & Renal Replacement Therapy

8.1 KDIGO AKI Classification, Etiologies & Diagnostic Evaluation 8.2 Continuous Renal Replacement Therapy (CRRT) vs Intermittent Hemodialysis 8.3 Indications & Timing for RRT in Critical Illness: AKIKI & STARRT-AKI

9 Chapter 9: Electrolyte, Acid-Base & Endocrine Emergencies

9.1 Severe Dysnatremias: Hyponatremia, Hypernatremia & Osmotic Demyelination 9.2 Potassium, Calcium, Magnesium & Phosphate Disorders 9.3 Complex & Mixed Acid-Base Disorders: Boston vs Copenhagen vs Stewart 9.4 Endocrine Crises: DKA, HHS, Thyroid Storm, Myxedema Coma & Adrenal Crisis

10 Chapter 10: Glycemic Control, Hyperammonemia, Pituitary & Adrenal Disorders

10.1 ICU Glycemic Control & Severe Hypoglycemia 10.2 Non-Hepatic Hyperammonemia & Metabolic Encephalopathy 10.3 Pituitary Emergencies, Adrenal Excess & Critical Illness-Related Corticosteroid Insufficiency

11 Chapter 11: Acute Coronary Syndromes & Cardiac Arrhythmias

11.1 Acute Coronary Syndromes & Mechanical Complications of Myocardial Infarction 11.2 Critical Tachyarrhythmias: Atrial Fibrillation with RVR, VT & VF 11.3 Critical Bradyarrhythmias, Conduction Blocks & Temporary Cardiac Pacing

12 Chapter 12: Acute Heart Failure, Valvular & Pericardial Emergencies

12.1 Acute Decompensated Heart Failure & Cardiogenic Pulmonary Edema 12.2 Acute Valvular Regurgitation & Prosthetic Valve Emergencies 12.3 Pericardial Tamponade & Acute Aortic Syndromes

13 Chapter 13: Myocardial Disease, Hypertensive & Cardiac Device Emergencies

13.1 Fulminant Myocarditis, Stress & Peripartum Cardiomyopathy, and Hypertrophic Cardiomyopathy 13.2 Hypertensive Emergencies & Ruptured Abdominal Aortic Aneurysm 13.3 Implanted Cardiac Devices, LVAD Emergencies & Electrical Storm

14 Chapter 14: Sepsis & Systemic Infectious Diseases

14.1 Sepsis-3 Definitions & Surviving Sepsis Campaign 2026 Guidelines 14.2 Refractory Septic Shock & Adjunctive Therapies 14.3 Multidrug-Resistant Pathogens & Antimicrobial Stewardship in the ICU

15 Chapter 15: ICU-Acquired & Severe Focal Infections

15.1 Hospital-Acquired & Ventilator-Associated Pneumonia 15.2 Central Line-Associated Bloodstream Infections & Catheter-Associated UTIs 15.3 Intra-Abdominal Sepsis, Necrotizing Soft Tissue Infections & CNS Infections

16 Chapter 16: Focal, Special-Host & Systemic Infections

16.1 CNS Infections Beyond Bacterial Meningitis: Encephalitis, Brain Abscess & Epidural Abscess 16.2 Infections in the Immunocompromised Host, Tropical & Bioterror Infections 16.3 Infective Endocarditis, Device Infections & Other Focal Cardiovascular Infections 16.4 Antimicrobial Pharmacokinetics, Allergy, Toxicity & Infection Prevention 16.5 Gastrointestinal & Hepatobiliary Infections: Fulminant C. difficile, Typhlitis, CMV Colitis & Abscesses

17 Chapter 17: Neurocritical Care & Coma

17.1 Coma, Altered Mental Status & Acute Delirium in the ICU 17.2 Status Epilepticus & Non-Convulsive Status Epilepticus 17.3 Acute Ischemic Stroke & Intracranial Hemorrhage

18 Chapter 18: Cerebrovascular Syndromes, Encephalopathy & Withdrawal States

18.1 Cerebral Venous Sinus Thrombosis, PRES & Reversible Cerebral Vasoconstriction Syndrome 18.2 Alcohol & Sedative Withdrawal, Wernicke Encephalopathy & Drug-Induced Encephalopathy

19 Chapter 19: Intracranial Hypertension & Neuromuscular Weakness

19.1 Intracranial Pressure Monitoring, Cerebral Perfusion & Tiered ICP Management 19.2 Acute Neuromuscular Respiratory Failure, ICU-Acquired Weakness & Brain Death Determination

20 Chapter 20: Traumatic Brain Injury, Spinal Cord Injury & Toxin-Mediated Paralysis

20.1 Traumatic Brain Injury Management & Paroxysmal Sympathetic Hyperactivity 20.2 Acute Spinal Cord Injury, Neurogenic Shock & Autonomic Dysreflexia 20.3 Toxin-Mediated Paralysis & Neuromuscular Crises: Botulism, Tetanus, Tick Paralysis & Myasthenic Crisis

21 Chapter 21: Gastrointestinal, Hepatic & Abdominal Emergencies

21.1 Acute Upper & Lower Gastrointestinal Bleeding in the ICU 21.2 Acute Liver Failure & Severe Acute Pancreatitis 21.3 Abdominal Compartment Syndrome & Acute Mesenteric Ischemia

22 Chapter 22: Luminal GI Emergencies & Complications of Cirrhosis

22.1 Esophageal, Gastric & Bowel Emergencies: Perforation, Obstruction, Ogilvie Syndrome & Colonic Ischemia 22.2 Complications of Cirrhosis: Alcohol-Associated Hepatitis, Hepatorenal Syndrome & Pulmonary Vascular Syndromes

23 Chapter 23: Trauma, Burns & Perioperative Critical Care

23.1 Polytrauma Resuscitation, Damage Control & Massive Transfusion 23.2 Severe Burn Injury, Inhalation Injury & Environmental Emergencies 23.3 Perioperative Critical Care for High-Risk Surgical Patients

24 Chapter 24: Thoracic Trauma, Environmental Injury & Obstetric Critical Care

24.1 Thoracic Trauma: Flail Chest, Pulmonary Contusion, Great Vessel & Tracheobronchial Injury 24.2 Environmental Injury: Drowning, Diving, Altitude, Heat, Cold, Electrical & Radiation 24.3 Obstetric & Genitourinary Emergencies and the Physiology of Pregnancy

25 Chapter 25: Transplantation, Donor Management & Post-Cardiac Surgery Care

25.1 Solid Organ Transplant Recipients & Deceased Donor Management 25.2 Post-Cardiac Surgery Critical Care: Bleeding, Tamponade, Low Output & Vasoplegia

26 Chapter 26: Hematologic Emergencies, Toxicology, Critical Ultrasound & ICU Liberation

26.1 Hematologic Emergencies in the ICU: HIT, DIC, TMA & Anticoagulant Reversal 26.2 Critical Care Toxicology, Toxidromes & Specific Antidotes 26.3 Critical Care Point-of-Care Ultrasound (POCUS) 26.4 ICU Liberation, Analgosedation, Goals of Care & Critical Care Ethics

27 Chapter 27: Transfusion Medicine, Hematologic & Oncologic Disorders

27.1 Transfusion Medicine: Products, Thresholds, Reactions & Apheresis 27.2 Red and White Cell Disorders, Hemoglobinopathies, Factor Deficiencies & Hypercoagulable States 27.3 Oncologic Emergencies, Hematopoietic Cell Transplant Complications & Cellular Therapy Toxicity

28 Chapter 28: Clinical Pharmacology, Adverse Drug Reactions & Specific Poisonings

28.1 Pharmacokinetic Principles, Dose Adjustment & Drug Interactions in Critical Illness 28.2 Adverse Drug Reactions: Anaphylaxis, Severe Cutaneous Reactions & Hyperthermic Syndromes 28.3 Specific Poisonings: Sodium-Channel Blockers, Lithium, Valproate, Theophylline, Iron, Sulfonylureas & Methemoglobinemia

29 Chapter 29: Ethics, Research Methods, Administration & Abdominal Ultrasound

29.1 Advance Care Planning, Nonbeneficial Treatment, Informed Consent & Confidentiality 29.2 Critical Care Research Methods, Statistics, IRB Oversight & Quality Improvement 29.3 Abdominal, Vascular & Procedural Point-of-Care Ultrasound

7.4 Post-Cardiac Arrest Care, Targeted Temperature Management & Neuroprognostication

Key Takeaways Explain This Topic AI

The post-cardiac arrest syndrome (PCAS) consists of four interrelated pathophysiological domains: hypoxic-ischemic brain injury, post-arrest myocardial dysfunction (ischemic stunning), systemic ischemia-reperfusion response (vasoplegic shock), and persistent precipitating pathology.

The landmark multicenter TTM2 trial (2021) demonstrated that targeted hypothermia at 33°C confers no 6-month survival or functional neurologic benefit compared with targeted normothermia (maintaining core temperature <= 37.5°C with active cooling initiated only for fever >= 37.8°C), while hypothermia causes significantly more hemodynamically compromising arrhythmias.

The 2025 AHA guideline recommends deliberate temperature control at a constant 32-37.5°C for at least 36 hours; ERC-ESICM guidance emphasizes preventing fever (> 37.7°C) for at least 72 hours. Routine 33°C hypothermia is no longer preferred.

AHA 2025 post-ROSC targets are MAP >= 65 mmHg, SpO2 90-98% (PaO2 60-105 mmHg), and PaCO2 35-45 mmHg; the BOX trial found no outcome difference between MAP targets of 63 and 77 mmHg or between restrictive and liberal oxygen targets.

Multimodal neuroprognostication must never be performed prior to 72 hours following ROSC (and only after rewarming and complete clearance of sedatives); poor outcome is reliably predicted by bilateral absent pupillary/corneal reflexes, bilateral absent N20 somatosensory evoked potentials (SSEP), high serum neuron-specific enolase (NSE > 60 mcg/L) at 48-72 hours, burst suppression on EEG, and diffuse cortical diffusion restriction on brain MRI.

Last updated: October 2026

Return of spontaneous circulation (ROSC) following cardiac arrest marks the initiation of a critical resuscitation phase. Patients resuscitated from prolonged cardiac arrest develop post-cardiac arrest syndrome (PCAS) , a complex systemic disorder encompassing hypoxic-ischemic brain injury, acute myocardial stunning, systemic ischemia-reperfusion injury, and ongoing pathology from the inciting arrest etiology. Intensive care management focuses on preventing secondary neurologic insults, stabilizing hemodynamics, maintaining strict normothermia, and executing objective multimodal neuroprognostication.

1. Pathophysiology of Post-Cardiac Arrest Syndrome (PCAS) The Four Pillars of Post-Cardiac Arrest Syndrome (PCAS):

┌────────────────────────────────────────────────────────────────────────┐
│ POST-CARDIAC ARREST SYNDROME │
├──────────────────────────┬──────────────────────────┬──────────────────┤
│ Hypoxic-Ischemic Brain │ Post-Arrest Myocardial │ Systemic │
│ Injury │ Dysfunction │ Ischemia- │
│ │ │ Reperfusion │
├──────────────────────────┼──────────────────────────┼──────────────────┤
│ • Selective neuronal │ • Global ischemic │ • Massive │
│ necrosis (CA1, cortex) │ myocardial stunning │ endotoxin and │
│ • Loss of cerebral │ • Reversible systolic & │ cytokine storm │
│ autoregulation │ diastolic impairment │ • Vasoplegic │
│ • Cytotoxic cerebral │ • Ejection fraction │ distributive │
│ edema & no-reflow │ recovers in 48–72 hr │ shock │
└──────────────────────────┴──────────────────────────┴──────────────────┘
1. Hypoxic-Ischemic Brain Injury (HIBI)

Brain tissue accounts for 20 % 20\% 20% of resting bodily oxygen consumption despite representing only 2 % 2\% 2% of total body mass. Interruption of cerebral blood flow precipitates rapid neuronal energy depletion within seconds:

Excitotoxicity & Calcium Influx: Depletion of intracellular ATP halts the Na + / K + \text{Na}^+/\text{K}^+ Na + / K + -ATPase pump, depolarizing the neuronal membrane and triggering massive vesicular release of glutamate into synaptic clefts. Glutamate overactivates postsynaptic NMDA and AMPA receptors, provoking an uncontrolled intracellular influx of calcium and sodium that activates apoptotic caspases, calpains, and endonucleases.

Selective Vulnerability: Neurons exhibiting the highest metabolic activity undergo early selective necrosis: hippocampal CA1 pyramidal neurons (accounting for severe post-arrest amnestic deficits), cerebellar Purkinje cells, striatal interneurons, and neocortical layers III and V.

Loss of Autoregulation & No-Reflow: Normal cerebral autoregulation—which maintains stable cerebral blood flow (CBF) between mean arterial pressures of 60 60 60 and 150 mmHg 150\text{ mmHg} 150 mmHg —is completely abolished. Cerebral perfusion becomes purely passive and pressure-dependent . Furthermore, microvascular endothelial swelling and microthrombi create the no-reflow phenomenon , causing focal ischemic areas despite restored macrovascular systemic perfusion.

2. Post-Arrest Myocardial Dysfunction

Patients routinely exhibit global left and right ventricular systolic and diastolic dysfunction resulting from transient, severe ischemic stunning. Cardiac index frequently falls below 2.0 L/min/m 2 2.0\text{ L/min/m}^2 2.0 L/min/m 2 , with elevated left-sided filling pressures. Fortunately, this dysfunction is largely reversible : myocardial performance typically nadirs within the first 24 to 48 hours and significantly recovers by 72 hours under inotropic and vasopressor support.

3. Systemic Ischemia-Reperfusion Response

Whole-body ischemia and subsequent reperfusion initiate a systemic inflammatory response syndrome (SIRS) that closely mirrors severe septic shock. Reperfusion unleashes high concentrations of circulating tumor necrosis factor-alpha (TNF- α \alpha α ), interleukin-1 (IL-1), and interleukin-6 (IL-6), accompanied by diffuse endothelial barrier breakdown, generalized capillary leak, profound vasoplegia, and an intravascular volume deficit.

2. Targeted Temperature Management: Trial Evolution & Guidelines

For nearly two decades, therapeutic hypothermia was widely regarded as the cornerstone of post-arrest neuroprotection. However, modern clinical trials have radically reshaped the evidence base: Evolution of Targeted Temperature Management (TTM) Evidence:

2002: Bernard & HACA Trials ──> Hypothermia (32–34°C) superior to uncontrolled hyperthermia
│
▼
2013: TTM1 Trial (N = 950) ──> 33°C vs 36°C demonstrated EQUAL 6-month mortality & neurologic outcome
│
▼
2021: TTM2 Trial (N = 1,900) ──> 33°C vs Targeted Normothermia (<=37.5°C) demonstrated EQUAL mortality,
EQUAL functional outcomes, and HIGHER arrhythmias in 33°C group
│
▼
2025 AHA / ERC-ESICM ──> Temperature control 32-37.5°C for >= 36 h (AHA);
fever prevention (> 37.7°C) for >= 72 h (ERC-ESICM)
Early Landmark Trials (2002)

In 2002, two seminal trials—the HACA Trial (Hypothermia After Cardiac Arrest) and Bernard et al. —demonstrated improved survival and favorable functional neurological recovery when comatose patients resuscitated from out-of-hospital ventricular fibrillation (VF) were cooled to 32 – 34 ∘ C 32\text{--}34^\circ\text{C} 32 – 3 4 ∘ C for 12 to 24 hours compared with "standard care". However, standard care groups in these early trials experienced untreated, high-grade hyperthermia ( > 38.5 ∘ C > 38.5^\circ\text{C} > 38. 5 ∘ C ), confounding whether hypothermia itself was protective or whether preventing fever was the true therapeutic mechanism.

The TTM1 Trial (Nielsen et al., NEJM 2013)

The TTM1 trial randomized 950 comatose out-of-hospital cardiac arrest (OHCA) patients with presumed cardiac etiology to targeted temperature management at either 33 ∘ C 33^\circ\text{C} 3 3 ∘ C or 36 ∘ C 36^\circ\text{C} 3 6 ∘ C for 28 hours, followed by controlled rewarming:

All-cause mortality at the end of the trial was identical: 50 % 50\% 50% in the 33 ∘ C 33^\circ\text{C} 3 3 ∘ C group versus 48 % 48\% 48% in the 36 ∘ C 36^\circ\text{C} 3 6 ∘ C group (hazard ratio 1.06; p = 0.51 p = 0.51 p = 0.51 ).

Neurological outcome evaluated by the Cerebral Performance Category (CPC) scale and modified Rankin Scale (mRS) at 180 days was equivalent.

The Definitive TTM2 Trial (Dankiewicz et al., NEJM 2021)

The international open-label, blinded-outcome TTM2 trial investigated whether targeted hypothermia provided any benefit over targeted normothermia with early fever management:

Study Design: 1,900 comatose adults with OHCA of any initial rhythm (shockable and non-shockable) were randomized to:

Hypothermia Group: Cooled to 33 ∘ C 33^\circ\text{C} 3 3 ∘ C with a feedback device, maintained for 28 hours, and rewarmed slowly at 0.33 ∘ C/hr 0.33^\circ\text{C/hr} 0.3 3 ∘ C/hr to 37 ∘ C 37^\circ\text{C} 3 7 ∘ C .

Normothermia Group: Maintained at ≤ 37.5 ∘ C \le 37.5^\circ\text{C} ≤ 37. 5 ∘ C ; active physical cooling devices were initiated only if body temperature reached ≥ 37.8 ∘ C \ge 37.8^\circ\text{C} ≥ 37. 8 ∘ C .

Primary Outcome: Death from any cause at 6 months occurred in 50 % 50\% 50% of patients in the hypothermia group versus 48 % 48\% 48% in the normothermia group (relative risk 1.04; 95 % CI 0.94 – 1.14 ; p = 0.37 95\%\text{ CI } 0.94\text{--}1.14; p = 0.37 95% CI 0.94 – 1.14 ; p = 0.37 ).

Functional Neurologic Outcome: Poor functional outcome (mRS 4 to 6) at 6 months was identical ( 55 % 55\% 55% vs 55 % 55\% 55% , relative risk 1.00).

Adverse Events: Arrhythmias resulting in hemodynamic compromise were significantly more frequent in the hypothermia group ( 24 % 24\% 24% vs 17 % 17\% 17% , p < 0.001 p < 0.001 p < 0.001 ).

Current Guideline Recommendations

The 2025 American Heart Association (AHA) guideline and the 2025 European Resuscitation Council and European Society of Intensive Care Medicine (ERC-ESICM) guideline establish:

Continuous Core Temperature Monitoring: Mandatory in all comatose post-cardiac arrest patients using an esophageal, bladder, or intravascular sensor (axillary and tympanic measurements are inadequate).

Deliberate Temperature Control (AHA 2025): For adults who do not follow commands after ROSC, select and maintain a constant temperature between 32 ∘ C 32^\circ\text{C} 3 2 ∘ C and 37.5 ∘ C 37.5^\circ\text{C} 37. 5 ∘ C (Class 1) for at least 36 hours (Class 2a). This includes hypothermic control ( 32 – 34 ∘ C 32\text{--}34^\circ\text{C} 32 – 3 4 ∘ C ) and normothermic or fever-prevention control ( 36 – 37.5 ∘ C 36\text{--}37.5^\circ\text{C} 36 – 37. 5 ∘ C ). Routine prehospital cooling with cold IV fluid is not beneficial.

Fever Prevention (ERC-ESICM 2022 temperature-control guideline, continued in 2025): Actively prevent fever, defined as > 37.7 ∘ C > 37.7^\circ\text{C} > 37. 7 ∘ C , for at least 72 hours in patients who remain comatose, using antipyretics and a cooling device when needed.

Hypothermia at 33 ∘ C 33^\circ\text{C} 3 3 ∘ C is Optional, Not Mandatory: After TTM2, routine 33 ∘ C 33^\circ\text{C} 3 3 ∘ C hypothermia is no longer favored over strict fever prevention, but it remains within the permitted range.

3. Resuscitation Targets: Hemodynamics, Oxygenation & Ventilation
Hemodynamic Goals

Target MAP: Maintain MAP ≥ 65 mmHg \text{MAP} \ge 65\text{ mmHg} MAP ≥ 65 mmHg (AHA 2025). In the BOX trial (Kjaergaard et al., NEJM 2022; 789 comatose OHCA survivors), targeting MAP 77 vs. 63 mmHg did not change death or severe disability (34% vs. 32%), so routinely higher MAP targets are not supported. Individualized higher targets are sometimes chosen for chronic hypertension, but this is not evidence-based.

Avoid Hypotension: Any episode of post-ROSC hypotension (systolic BP < 90 mmHg < 90\text{ mmHg} < 90 mmHg or MAP < 65 mmHg \text{MAP} < 65\text{ mmHg} MAP < 65 mmHg ) is independently associated with doubled in-hospital mortality. Norepinephrine is the initial vasopressor of choice.

Oxygenation Targets: Avoiding the Hypoxia-Hyperoxia Paradox

Normoxia Goal: Maintain 100% FiO2 only until saturation can be measured reliably, then titrate to SpO 2 90–98% \text{SpO}_2\text{ 90--98\%} SpO 2 90–98% ( PaO 2 \text{PaO}_2 PaO 2 about 60 – 105 mmHg 60\text{--}105\text{ mmHg} 60 – 105 mmHg ) per AHA 2025; European guidance likewise advises avoiding both hypoxemia and hyperoxemia. The oxygen arm of the BOX trial (PaO2 68-75 vs. 98-105 mmHg) showed no outcome difference.

The Peril of Hyperoxia: Hyperoxia (defined as PaO 2 > 200 – 300 mmHg \text{PaO}_2 > 200\text{--}300\text{ mmHg} PaO 2 > 200 – 300 mmHg ) is cytotoxic during reperfusion. Excess dissolved oxygen accelerates mitochondrial production of reactive oxygen species (superoxide, hydroxyl radicals), induces intense cerebral and coronary vasoconstriction, oxidizes cellular lipids and proteins, and is associated with significantly worse functional neurologic outcomes.

Ventilation Targets: The Danger of Hypocapnia

Normocapnia Goal: Titrate minute ventilation strictly to maintain arterial PaCO 2 \text{PaCO}_2 PaCO 2 between 35 and 45 mmHg 35\text{ and }45\text{ mmHg} 35 and 45 mmHg .

Physiology of Arterial CO 2 \text{CO}_2 CO 2 on Cerebral Blood Flow: Carbon dioxide is the most potent physiological regulator of cerebral arteriolar diameter. Hypocapnia (PaCO2 < 35 mmHg) induces profound cerebral vasoconstriction, causing severe secondary ischemic brain injury. Hypercapnia (PaCO2 > 45 mmHg) induces cerebral vasodilation, increasing cerebral blood volume and aggravating intracranial hypertension.

Note

When evaluating arterial blood gases in patients undergoing hypothermia, blood gases must be interpreted without temperature correction (the alpha-stat method ) to reflect standard physiologic cellular enzymatic kinetics.

Early Coronary Angiography

STEMI Present: Immediate emergency coronary angiography and PCI are mandatory for all post-arrest patients whose initial ECG reveals ST-segment elevation.

No STEMI Present: The randomized COACT (Lemkes et al., NEJM 2019) and PEARL trials demonstrated that in hemodynamically stable post-ROSC patients without ST-segment elevation, immediate emergent angiography does not improve 90-day survival compared with delayed, selective angiography. Emergent catheterization in non-STEMI patients should be reserved for those with cardiogenic shock, electrical instability, or ongoing ischemic symptoms.

4. Multimodal Neuroprognostication Framework

Neuroprognostication determines the likelihood of severe, irreversible hypoxic-ischemic brain damage and guides decisions regarding withdrawal of life-sustaining therapy (WLST). Premature, flawed prognostication can create a fatal self-fulfilling prophecy , where therapy is withdrawn from a patient who harbored potential for functional recovery. Multimodal Neuroprognostication Timeline & Evaluation:

[ ROSC Occurs ] ──> Targeted Normothermia / Fever Prevention (>= 72 Hours)
│
▼
[ REWARMING & COMPLETE SEDATIVE CLEARANCE ]
│
▼
===========================================
MANDATORY MINIMUM WAITING PERIOD: 72 HOURS
===========================================
│
┌─────────────────┼─────────────────┐
▼ ▼ ▼
Clinical Exam Electrophysiology Biomarkers & Imaging
(>= 72 Hours) (>= 24–72 Hours) (24–72 Hr & Days 2–5)
Bilateral absent • Bilateral absent • Serum NSE > 60–80 µg/L
pupillary light N20 on SSEP at 48–72 hours
reflex (PLR) • Malignant EEG: • Brain CT: GM/WM < 1.10
Bilateral absent Burst suppression • Brain MRI: Diffuse DWI
corneal reflex or Status restriction (Days 2–5)
The Mandatory 72-Hour Rule & Sedation Clearance

Guidelines strictly mandate that formal multimodal neuroprognostication must never be finalized prior to 72 hours after ROSC . In patients managed with hypothermia, the 72-hour clock begins after complete rewarming to normothermia (often day 4 to 5 post-arrest). Confounding residual sedation, neuromuscular blockade, severe hypothermia, sepsis, and metabolic derangements must be completely eliminated.

Multimodal Diagnostic Modalities

Modality Optimal Timing Specific Finding Predicting Poor Neurological Outcome False-Positive Rate (FPR) & Reliability

Clinical Examination: Pupillary Reflex ≥ 72 hours \ge 72\text{ hours} ≥ 72 hours post-ROSC Bilateral absent pupillary light reflex (PLR) ; automated quantitative pupillometry demonstrating Neurological Pupil index (NPi) < 2 < 2 < 2 False-positive rate < 1 % < 1\% < 1% ; highly reliable objective sign of irreversible brainstem injury.

Clinical Examination: Corneal Reflex ≥ 72 hours \ge 72\text{ hours} ≥ 72 hours post-ROSC Bilateral absent corneal reflex FPR ≈ 1 – 2 % \approx 1\text{--}2\% ≈ 1 – 2% ; must confirm complete absence of neuromuscular blockade and deep sedation.

Clinical Examination: Motor Response ≥ 72 hours \ge 72\text{ hours} ≥ 72 hours post-ROSC Absent motor response or extensor posturing (M ≤ 2 \le 2 ≤ 2 ) to noxious stimuli Unacceptably high FPR ( 10 % to 25 % 10\%\text{ to }25\% 10% to 25% ) ; must never be used in isolation to prognosticate.

Somatosensory Evoked Potentials (SSEP) ≥ 24 – 72 hours \ge 24\text{--}72\text{ hours} ≥ 24 – 72 hours post-ROSC Bilateral absence of cortical N20 potentials following electrical median nerve stimulation Gold standard electrophysiologic predictor ; FPR < 0.5 % < 0.5\% < 0.5% ; largely resistant to metabolic confounders and sedation.

Continuous Electroencephalography (EEG) First 24 to 72 hours 24\text{ to }72\text{ hours} 24 to 72 hours Highly malignant patterns: suppressed background ( < 10 μ V < 10\,\mu\text{V} < 10 μ V ), burst suppression with identical bursts, or refractory electrographic status epilepticus FPR < 1 % < 1\% < 1% when persistent beyond 24-48 hours and corroborated by other modalities; reactive normal background strongly predicts recovery.

Serum Biomarkers: Neuron-Specific Enolase (NSE) 48 and 72 hours 48\text{ and }72\text{ hours} 48 and 72 hours post-ROSC Serum NSE > 60 – 80 μ g/L \text{NSE} > 60\text{--}80\,\mu\text{g/L} NSE > 60 – 80 μ g/L with rising trajectory between 24, 48, and 72 hours High levels reflect massive structural axonal and neuronal necrosis; hemolyzed samples cause false-positive elevations. The 2025 AHA guideline also recognizes serum neurofilament light chain (NfL) as a prognostic biomarker where the assay is available.

Brain Non-Contrast CT Within 24 to 48 hours 24\text{ to }48\text{ hours} 24 to 48 hours Generalized sulcal effacement and loss of gray-white matter differentiation (gray/white ratio < 1.10 – 1.15 < 1.10\text{--}1.15 < 1.10 – 1.15 at basal ganglia level) Reflects severe diffuse cytotoxic cerebral edema; highly specific when marked.

Brain Magnetic Resonance Imaging (MRI) Days 2 to 5 2\text{ to }5 2 to 5 post-ROSC Extensive, diffuse cortical and deep gray matter diffusion restriction on diffusion-weighted imaging (DWI) with corresponding low ADC Extremely high anatomical resolution; demarcates irreversible cytotoxic neuronal death across the cerebral mantle.

Caution

Early myoclonus (motor twitches within 24-48 hours) was historically designated "myoclonic status epilepticus" and deemed universally fatal. However, contemporary cohorts demonstrate that some patients with early myoclonus achieve functional recovery. Do not withdraw care based on myoclonic jerks alone; mandate SSEP and EEG confirmation.